

Lung Adenocarcinoma

Tumour Stage	IA1		IA2		IA3		IB		II		IIIA	
Patients (n)	41		117		64		71		124		150	
	n	%	n	%	n	%	n	%	n	%	n	%
EGFR	4	9.8	17	14.5	12	18.8	15	21.1	11	8.9	13	8.7
KRAS G12C	10	24.4	19	16.2	16	25.0	8	11.3	23	18.5	22	14.7
KRAS non G12C	14	34.1	19	16.2	15	23.4	15	21.1	33	26.6	35	23.3
BRAF V600E	1	2.4	6	5.1	0	0.0	0	0.0	2	1.6	1	0.7
BRAF non V600E	1	2.4	9	7.7	1	1.6	4	5.6	3	2.4	4	2.7
ERBB2	0	0	1	0.9	0	0.0	1	1.4	1	0.8	2	1.3
ALK	0	0	3	2.6	2	3.1	0	0.0	0	0.0	2	1.3
ROS1	0	0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0
RET	0	0	1	0.9	2	3.1	0	0.0	0	0.0	1	0.7
METEx14skip	0	0	3	2.6	1	1.6	2	2.8	4	3.2	3	2.0

Tumour Stage	IA1		IA2		IA3		IB		II		IIIA	
Patients (n)	41		117		62		68		119		144	
	n	%	n	%	n	%	n	%	n	%	n	%
PD-L1 (TPS ≥ 1)	14	34.1	46	39.3	27	43.5	31	45.6	54	45.4	69	47.9